Provided herein are compositions, methods, uses, and articles of manufacture for iodine treatment on mucosal membranes, and treatment of respiratory pathogens in this way—e.g., by inhalation and combined with the evaporation of steam. In certain embodiments, iodine treatment encompasses administration of compounds that release molecular iodine and/or physiologically active iodine-containing compounds.

A method of inducing anesthesia in a subject is provided. In some embodiments, the method provides administering to the subject via the respiratory system or via injection, an effective amount of a compound or a mixture of compounds selected from the group consisting of methyl-ethyl ethers, methyl-isopropyl ethers, and methyl-propyl ethers.

Apparatus and methods are described for use with a vaporizer that vaporizes at least one active ingredient of a material. In response to receiving a first input to the vaporizer, the material is heated, in a first heating step. An indication of the temperature of the material is detected, and, in response to detecting an indication that the temperature of the material is at a first temperature, the first heating step is terminated, by withholding causing further temperature increase of the material. The first temperature is less than 95 percent of the vaporization temperature of the active ingredient. Subsequently, a second input is received at the vaporizer. In response thereto, the material is heated to the vaporization temperature, in a second heating step. Other applications are also described.

Disclosed herein are methods for prophylactic treatment of acute coronary syndrome (ACS) comprising administering, by inhalation, an effective amount of a pharmaceutical composition comprising at least one anticoagulant or antiplatelet agent to a subject in need thereof, wherein the anticoagulant or antiplatelet agent first enters the heart via the left atrium.

The invention relates to the field of medicine, and more particularly to emergency medical assistance. A respiratory intervention is performed on a patient with an artificial gas-air mixture having an increased content of argon of at least 30 vol %, enabling this artificial gas-air mixture to be effective continuously throughout the procedure. Furthermore, the respiratory gaseous medium has an increased content of oxygen with xenon being added and has the following composition: 1-10 vol % of xenon; 30-35 vol % of argon; 60-65 vol % of oxygen. The intervention on the patient with the artificial gas-air mixture of the composition mentioned is performed for 20-40 minutes or more, until specialized medical assistance is given. The method makes it possible to increase the effectiveness, safety and rapidity of relieving acute cerebral and cardiac ischemia, and to reduce the risk of developing an acute cerebral stroke or myocardial infarction.

The present disclosure is directed to a method of treating a neuropsychiatric disorder. This method involves selecting a subject having the neuropsychiatric disorder and administering to the selected subject a preparation of glial progenitor cells at a dosage effective to treat the neuropsychiatric disorder in the subject. Another aspect of the disclosure is directed to a method of treating a neuropsychiatric disorder that includes selecting a subject having the neuropsychiatric disorder and administering, to the selected subject, a potassium (K.sup.+) channel activator at a dosage effective to restore normal brain interstitial glial K.sup.+ levels in the selected subject and treat the neuropsychiatric disorder is also disclosed.

A method for treating or mitigating Parkinson's disease (PD) symptoms or progression, including administering an effective amount of nicotine to a subject in need thereof, via inhalation using a nicotine inhaler or via nasal spray using a nicotine nasal spray. Significant dose-dependent improvement of all symptoms by nicotine inhaler or nicotine nasal spray is expected. A novel treatment in PD is thus provided.

Disclosed are compositions containing chemical constituents from plants, uses of these compositions and methods for making them. In various embodiments, the present invention relates to an improved modes of administration of herbal remedies.

The present invention describes cannabinoid formulations that combine cannabinoids, such as CBD, with other active agents within the NAD+ precursor class of compounds which, in combination, provide synergistic anti-inflammatory effects. These preparations are capable of increasing anti-inflammatory effects when compared to each individual compound, and are further capable of delivery through a variety of administration routes.

The present invention describes new formulations of semiochemical compounds for mammals in wick diffusers particularly effective in controlling the diffusion of several semiochemicals having different volatilities over long periods of time and independently of the temperature and humidity conditions.